Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
NEW YORK, April 11, 2018 -- Safirstein Metcalf LLP, announces that a class action lawsuit was filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Cancer Genetics, Inc. (NASDAQ:CGIX) (“Cancer Genetics” or the “Company”) securities between March 23, 2017 and April 2, 2018 (the “Class Period”).
If you purchased or acquired Cancer Genetics securities during the class period, and would like more information about the shareholder class action, please contact Safirstein Metcalf LLP at 1-800-221-0015, or email [email protected]
If you wish to serve as lead plaintiff, you must move the Court no later than June 4, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member.
According to the complaint, the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On April 2, 2018, the Company reported that, following its CEO’s departure, it conducted a comprehensive review of its strategy and organization. This led the Company to record a bad debt expense of $4.4 million and write off $1.8 million of its accounts receivable in the fourth quarter, with a significant portion related to collection issues with accounts receivables recorded after 2015. The Company also reported that, on December 31, 2017, its “cash position and history of losses required management to assess [its] ability to continue operating as a going concern[.]” Following this news, shares of Cancer Genetics fell $0.55 per share or over 33% to close at $1.10 per share on April 3, 2018.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP
Peter Safirstein, Esq.
1250 Broadway
27th Floor
New York, NY 10001
1-800-221-0015
